DIA CALL FOR ABSTRACTS

SUBMISSION DEADLINE: APRIL 18

Real-World Evidence Conference

OCTOBER 16-17 | WESTIN SAN DIEGO HOTEL | SAN DIEGO, CA

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DETAILS AND GUIDELINES
SUBMISSION DEADLINE: APRIL 18

Are you a professional involved in real-world data (RWD) sourcing, real-world evidence (RWE) generation, integration into decision-making by payers, regulators, and healthcare systems/providers/patients, or policy development pertaining to drugs, biologics, or devices? If so, DIA wants to hear from you! The DIA Real-World Evidence Conference, to be held October 16-17 in San Diego, CA, will explore innovative applications of RWE and deliver key insights from organizations leveraging this knowledge to advance healthcare decision-making and cutting-edge research.

The Real-World Evidence Conference Program Committee is seeking abstract proposals for Presentations, Sessions, and Short Courses related to the topics listed below. As this conference is attended by academic, payer, regulatory, biopharma/medical device industry, health authority, advocacy, and service provider professionals, topics inclusive of but not limited to those listed below will be considered by the Program Committee. Real-world use cases, regardless of success, and lessons learned are highly encouraged.

Expectations for Virtual Short Course Proposals:

Short Course(s) will be conducted virtually approximately 1 week prior to the live RWE Conference. The duration of the course is 3.5 hours. Proposals should go beyond traditional presentations and focus on interactive, didactic learning. Please specify in your submission:

- Names of speakers to include representation from multiple sectors (e.g., industry, academia, regulatory, payer, and service providers)
- Engagement strategies (e.g., interactive exercises, small-group learning, etc.)

Topics of Interest Include:

- Decision-making Use Cases Including Regulatory Agency, Health Technology Assessment Payer, Service Provider, or Drug/Device/Biologics Industry Perspectives
- Target Identification & RWD/E, including the intersection of omics studies and observational research
- Regulatory and Market Access Applications
  - Supporting drug/vaccine approval, reimbursement, and label expansion or modification
  - Post-market commitments (PMR/PMC/PASS/PAES) and benefit-risk assessment
  - Enhancing efficiency in subsequent authorizations
  - RWE-driven clinical recommendations and market access strategies
- Regulatory and Payment Pathways
  - Optimizing RWE for clinical recommendations and market access
  - Enhancing efficiency in subsequent authorizations
- Innovations in Technology, Methodology, and Operational Excellence to Support RWD and RWE, such as:
  - Artificial intelligence
  - Machine learning
  - Digital health technologies
  - Tokenization
  - Synthetic data
  - Data curation and quality improvement
- RWD Data Standards, Quality, and Use in Practice
  - Retrospective data and prospective data quality considerations
  - Practical implementation of RWD/E guidance
  - Data Interoperability Standards
- Emerging RWD Sources and Systems (North America, Europe, and Asia)
  - Expanding geographic coverage
  - Government, private sector, academic
  - Therapeutic area-specific RWD resources
- Governance, Access, and Harmonization
  - Data privacy, security, and governance challenges
  - International convergence initiatives for RWD and RWE
- Patient, Patient Advocate, and Special Population Perspectives on RWD and RWE
- RWD and RWE in Study Designs Supporting Clinical Development and Post-Marketing Needs
  - De-risking pivotal trial designs
  - Establishing a stage-gate framework for clinical programs
  - Decentralized trials
  - Traditional RCTs integrating RWD
  - Trials in clinical practice settings, with pragmatic elements
  - External controlled trials
  - Observational studies to support pivotal study design
- Health Equity and RWD/RWE
  - RWE as a strategy to support diversity in clinical development
  - Incorporating social determinants of health into RWD/E analyses to enhance understanding of health outcomes and interventions
- Therapeutic Area and/or Modality Considerations for RWE
- Shared Learnings Among Public-Private and Cross-Industry Consortia and Initiatives Addressing RWD and RWE

Abstract Submission Deadline: Friday, April 18, 2025

Notification: Week of June 9, 2025

Final PowerPoint Presentations Due: September 25, 2025

Meeting Dates: October 16-17, 2025

Please submit all abstracts online at: DIAglobal.org/Abstracts

Questions: Contact Damisha White, Project Manager, Specialty Meetings, at Damisha.White@DIAglobal.org

Submit Your Abstract at **DIAglobal.org/Abstracts**

CALL FOR PRESENTATION ABSTRACTS

SUBMISSION DEADLINE: APRIL 18

GENERAL SUBMISSION REQUIREMENTS

- All proposals must be submitted online
- For complete submission requirements and to submit your abstract go to **DIAglobal.org/Abstracts**
- DIA requires speaker presentations to be non-commercialized, objective, and fair balanced. Company logos are not permitted to be included in slide presentations, per ACCME Standards for Commercial Support. In addition, speaker clothing/backgrounds may not carry logos or other company specific emblems. In this way, DIA activities will be educational, rather than commercial and promotional. Please view **full policy concerning promotion of products and services from the podium**.

SUBMISSION TIPS

- Submissions with practical content and shared experiences are encouraged.
- Theoretical topics and content are acceptable but should be supported with proof of concepts and use cases.
- Diverse topics and sessions are welcomed and encouraged within the scope of the conference.
- Please select the interest area that best fits with your proposal. If your topic is relevant to more than one interest area, please indicate that in your abstract summary.
- Abstracts should be written using clear language and descriptions to provide enough clarity for the selection committee to review and understand.

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- **Participant Disclosure Information:** All abstract authors must disclose relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices.
- All authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download.

SUBMISSION GUIDELINES

Submitting a PRESENTATION ABSTRACT (All abstracts must be submitted online)

15-20-minute presentation, bundled with other presentations as deemed appropriate by the Program Committee to create a session. Abstract author is considered the presenter (co-presenters are not permitted) and will be responsible for:

- Adhering to the program development guidelines and timelines
- Working with Session Chair and other presenters in creating a balanced program offering
- Preparing and delivering a PowerPoint presentation

Submitting a SESSION ABSTRACT (All abstracts must be submitted online)

60-75-minute total session. Abstract author will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting speakers and ensuring good representation/diversity in their selection (no more than one speaker per company per session). Maximum of 3 speakers per session. Please list all prospective speaker names and organizations in submission.
- Working with the Session Chair to communicate with speakers regarding their role in the session

Submitting a SHORT COURSE ABSTRACT (All abstracts must be submitted online)

Three-hour, interactive presentation delivered in small group format. Abstract author is considered the Short Course Lead Instructor and will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting co-instructors and ensuring good representation/diversity in their selection
- Communicating with co-instructors regarding their role in the short course and reviewing presentation materials (note: PowerPoint presentations are required from each instructor)
- Managing the short course, including the facilitation of audience questions and interactions

SUBMISSION GUIDELINES

The following information will be requested at the time of submission. ***DIAglobal.org/Abstracts***

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Author Information

Abstract Information

Benefit-Driven, Proactive Abstract Topic/Title: (125 characters including spaces)

Interest Area: Choose from the drop down

Keywords: Provide one or more keywords to highlight your abstract. Examples of keywords: Personalized Medicine, Health Technology Assessment, etc. (100 characters)

Level of Difficulty: Beginner, Intermediate, or Advanced

Featured Learning Points: Provide 2-3 learning objectives that clearly explain what participants should be able to do after attending this event. For a list of suggested verbs to create these objectives, click here. (400 Characters)

Overview: *Please provide 3-4 sentences summarizing your abstract. This summary will be used as the overview description in the DIA program for marketing purposes (250 Characters including spaces)

Abstract Details: *Please provide complete details about your abstract. Information such as scientific, technical, process issues, design/methods, results/outcomes, case studies, statistics, key findings, etc., that would support your proposal should be included here. This information will be used by the Program Committee to learn more about the purpose of your abstract. Is there an interactive component to your topic? If so, please indicate in the abstract details how you would be able to include an interactive learning experience for attendees. (2000 Characters including spaces)

Submit Your Abstract at **DIAglobal.org/Abstracts**